

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4235375

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SPIROGEN SÀRL	01/12/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEDIMMUNE LIMITED
<b>Street Address:</b>	MILSTEIN BUILDING, GRANTA PARK
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	ENGLAND
<b>Postal Code:</b>	CB21 6GH
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14769787
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(703)918-2262
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7033942253
<b>Email:</b>	jmeigs@wcsr.com
<b>Correspondent Name:</b>	WOMBLE CARLYLE SANDRIDGE & RICE, LLP
<b>Address Line 1:</b>	P.O. BOX 7037
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30357-0037
<b>ATTORNEY DOCKET NUMBER:</b>	S69697 1110US.PCT
<b>NAME OF SUBMITTER:</b>	JULIE BROADUS MEIGS, PH.D.
<b>SIGNATURE:</b>	/julie broadus meigs/
<b>DATE SIGNED:</b>	01/20/2017
<b>Total Attachments: 6</b>	
source=sc1602 - Assignment - Spirogen to Medimmune#page1.tif	
source=sc1602 - Assignment - Spirogen to Medimmune#page2.tif	
source=sc1602 - Assignment - Spirogen to Medimmune#page3.tif	
source=sc1602 - Assignment - Spirogen to Medimmune#page4.tif	
source=sc1602 - Assignment - Spirogen to Medimmune#page5.tif	
source=sc1602 - Assignment - Spirogen to Medimmune#page6.tif	

## CONFIRMATORY ASSIGNMENT

### PARTIES

- (1) **SPIROGEN SÀRL** of Rue de Grand-Chêne 5, 1003 Lausanne, Switzerland (and formerly of Rue Saint-Pierre 2, c/o Michael Forer, CH-1003 Lausanne, Switzerland) ("Assignor")
- (2) **MEDIMMUNE LIMITED** of Milstein Building, Granta Park, Cambridge, CB21 6GH, England ("Assignee")

### INTRODUCTION

- (A) The Assignor is a co-applicant in the Patent Applications.
- (B) The Assignor and the Assignee entered into an agreement dated 13 October 2014 ("the 2014 Agreement") whereby the Assignor assigned its share in the Patent Applications to the Assignee.
- (C) The parties wish to enter this Agreement for the purpose of confirming the assignment under the 2014 Agreement and recording that assignment.

### AGREEMENT

#### 1. DEFINITIONS

In this Agreement, including the Introduction, the following words have the following meanings:

**Agreement** means this agreement including the Schedule; and

**Patent Applications** means the patent applications listed in the Schedule to this Agreement and any subsequent patent applications and granted patents in any country claiming priority from them.

**2. ASSIGNMENT**

For the consideration of Euro 1.00 and the good and valuable consideration set out in the 2014 Agreement, the receipt and sufficiency of which is acknowledged by the Assignor, the Assignor hereby


- (a) confirms the assignment to the Assignee of all its share in all right, title and interest in the Patent Applications; and
- (b) confirms that the assignment included in relation to its share in each of the Patent Applications:
  - (i) right to claim priority from and to prosecute and obtain a grant of patent; and
  - (ii) right to file divisional applications, contraventions, confirmations-in-part and other continuing applications based thereon and to prosecute and obtain a grant of patent on each and any such divisional application;
  - (iii) in respect of each and any invention disclosed in the Patent Applications, the right to file an application, claim priority from such application, and prosecute and obtain grant of patent or similar protection; and in respect of any application therefor, the absolute entitlement to any patents granted pursuant thereto or filed as aforesaid in or in respect of any country or territory in the world;
  - (iv) all rights and privileges pertaining thereto, including the right to bring, make, oppose, defend and appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Patent Applications or any patents granted on any of the applications in the Patent Applications or filed as aforesaid, whether occurring before on or after the date of this Agreement; and
  - (v) the right to extend to or register in or in respect of any country or territory in the world each and any of the Patent Applications, and each and any of the applications comprised in the Patent Applications or filed as aforesaid, and to extend to or register in, or in respect of, any country or territory in the world

any patent or like protection granted on any of such applications.

(c) to the extent any of the Assignor's right, title or interest in the Patent Applications has not previously been assigned, the Assignor assigns with effect from 13 October 2014 all that right, title and interest to the Assignee under this Agreement.

(d) The Assignee hereby confirms that is has accepted and hereby accepts the assignment to it of the Patent Applications together with all rights and obligations pertaining thereto.

Signed by: Christopher Winter  
on behalf of **SPIROGEN SARL**



Title: Authorised signatory

Date:

17 January 2016

WITNESS 1:

Signature of Witness 1:



Name:

Beate A. Golden

Address:

Occupation:

Keer Amin  
MedImmune Limited  
Milestone Building, Granta Park  
Cambridge CB21 6GH, UK  
Tel: 01223 471 471  
Fax: 01223 471 472  
Registered No. 2451177

WITNESS 2:

Signature of Witness 2:



Name:

Matthew Horton

Address:

Occupation:

Matthew Horton  
MedImmune Limited  
Milestone Building, Granta Park  
Cambridge CB21 6GH, UK  
Tel: 01223 471 471  
Fax: 01223 471 472  
Registered No. 2451177

Signed by: Christopher Winter  
on behalf of **MEDIMMUNE  
LIMITED**

*C D Winter*

Title: Authorised signatory

Date:

*12 January 2016*

WITNESS 1:

Signature of Witness 1:

*Barbara Leyden*

Name:

*BARBARA LEYDEN*

Address:

Occupation:

*Legal Admin*  
MedImmune Limited  
Milestone Building, Grants Park  
Cambridge CB21 6GH, UK  
Tel: 01223 471 471  
Fax: 01223 471 472  
Registered No. 2381177

WITNESS 2:

Signature of Witness 2:

*M. Hinton*

Name:

*Matthew Hinton*

Address:

Occupation:

*Contracts Manager*

MedImmune Limited  
Milestone Building, Grants Park  
Cambridge CB21 6GH, UK  
Tel: 01223 471 471  
Fax: 01223 471 472  
Registered No. 2381177

**Schedule – the Patent Applications**

Applicant/Owner	Jurisdiction Name	General Status	Application No.	Publication No.	Filing Date
SPIROGEN SARL	Argentina	Pending	20140100571		24 February 2014
SPIROGEN SARL	Australia	Pending	2014218730		21 February 2014
SPIROGEN SARL	Brazil	Pending	BR112015019909-7		21 February 2014
SPIROGEN SARL	Canada	Published	2,901,114	2,901,114	21 February 2014
SPIROGEN SARL	Chile	Pending	02357-2015		21 February 2014
SPIROGEN SARL	China	Published	201480018139.7	105164159A	21 February 2014
SPIROGEN SARL	Colombia	Pending	15-223.132		21 February 2014
SPIROGEN SARL	European Patent Office	Pending	14753730.2		21 February 2014
SPIROGEN SARL	India	Pending	3106/KOLNP/2015		21 February 2014
SPIROGEN SARL	Indonesia	Pending	P00 2015 05912		21 February 2014
SPIROGEN SARL	Israel	Published	240438		21 February 2014
SPIROGEN SARL	Japan	Pending	2015-559019		21 February 2014
SPIROGEN SARL	Malaysia	Pending	PI 2015002086		21 February 2014

SPIROGEN SÀRL	Mexico	Pending	MX/ai/2015/010682		21 February 2014
SPIROGEN SÀRL	New Zealand	Pending	712331		21 February 2014
SPIROGEN SÀRL	Peru	Pending	001797-2015/DIN		21 February 2014
SPIROGEN SÀRL	Philippines	Pending	1-2015-501846		21 February 2014
SPIROGEN SÀRL	Russian Federation	Pending	2015140122		21 February 2014
SPIROGEN SÀRL	Saudi Arabia	Pending	515360928		21 February 2014
SPIROGEN SÀRL	Singapore	Pending	11201506650P		21 February 2014
SPIROGEN SÀRL	South Africa	Pending	2015/07012		21 February 2014
SPIROGEN SÀRL	South Korea	Pending	10-2015-7026213		21 February 2014
SPIROGEN SÀRL	Taiwan	Published	103105978	201442728	21 February 2014
SPIROGEN SÀRL	Thailand	Pending	1501004791		21 February 2014
SPIROGEN SÀRL	United States	Pending	14/769,787		21 August 2015
SPIROGEN SÀRL	United States	Expired	61/768,368		22 February 2013
SPIROGEN SÀRL	Vietnam	Pending	1-2015-03483		21 February 2014
SPIROGEN SÀRL	WIPO	Expired	PCT/US2014/017810	WO/2014/130879	21 February 2014

PATENT